Table 1

Summary of reports of HSCT for MS

	n	Age	MS subtype (n)			Disease duration (years)	EDSS	Conditioning			Follow-up time (months)	PFS		MRI		NEDA		TRM	Prognostic factors
	n	Age	RRMS	SPMS	PPMS	Disease duration (years)	EDSS	BEAM	Cy	Other	Follow-up time (months)	Timepoint	Percentage	Timepoint	Percentage	Timepoint	Percentage	Percentage	Prognostic factors
Burman et al 37	(41*) 48	31†	34	5	2	5.5‡	6‡	34	6		47†	60	77	60	85	60	68	0	Gd+ at baseline
Nash et al 40	24	38‡	24			4.9‡	4.5‡	24			62‡	60	91	60	86	60	69	0
Burt et al 38	(145*) 151	37‡	118	27		61‡	4‡		145		30†	48	87	n/a	n/a	48	68	0	Disease duration <10 years RRMS vs SPMS fever in the peritransplant period
Atkins et al 39	24	34‡	12	12		5.8‡	5‡			24	80‡	60	70	60	100	60	70	4.2

*Only evaluated for safety.
†Mean.
‡Median.
EDSS, expanded disability status score; HSCT, haematopoietic stem cell transplantation; MS, multiple sclerosis; NEDA, no evidence of disease activity; TRM, treatment-related mortality;RRMS, relapsing-remitting MS SPMS, secondary progressive MS; PPMS, primary progressive MS; PFS, progression-free survival; BEAM, the combination ofcarmustine (BCNU), etoposide, cytarabine (Ara-c), and melphalan; n/a, not available; Cy, cyclophosphamide40.